View in EDS

Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

Saved in:
Bibliographic Details
Title: Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.
Authors: Berdel AF; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Ronnacker J; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Wenge DV; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA., Kolloch LJ; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Berning P; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Center for Molecular and Cellular Oncology, Yale School of Medicine, New Haven, CT., Angenendt L; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland., Brix TJ; Medical Data Integration Center, Institute of Medical Informatics, University of Münster, Münster, Germany., Westermann A; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Wethmar K; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Kessler T; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Kerkhoff A; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Mesters RM; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Reicherts C; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Mikesch JH; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Berdel WE; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Lenz G; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Schliemann C; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany., Stelljes M; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.
Source: Blood neoplasia [Blood Neoplasia] 2025 Nov 06; Vol. 3 (1), pp. 100181. Date of Electronic Publication: 2025 Nov 06 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41509995
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Berdel+AF%22">Berdel AF</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Ronnacker+J%22">Ronnacker J</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Wenge+DV%22">Wenge DV</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Kolloch+LJ%22">Kolloch LJ</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Berning+P%22">Berning P</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Center for Molecular and Cellular Oncology, Yale School of Medicine, New Haven, CT.<br /><searchLink fieldCode="AU" term="%22Angenendt+L%22">Angenendt L</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.; Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule Zurich, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Brix+TJ%22">Brix TJ</searchLink>; Medical Data Integration Center, Institute of Medical Informatics, University of Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Westermann+A%22">Westermann A</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Wethmar+K%22">Wethmar K</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Kessler+T%22">Kessler T</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Kerkhoff+A%22">Kerkhoff A</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Mesters+RM%22">Mesters RM</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Reicherts+C%22">Reicherts C</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Mikesch+JH%22">Mikesch JH</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Berdel+WE%22">Berdel WE</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Lenz+G%22">Lenz G</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Schliemann+C%22">Schliemann C</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Stelljes+M%22">Stelljes M</searchLink>; Department of Medicine A, Hematology/Oncology, University Hospital Münster, Münster, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918841988906676%22">Blood neoplasia</searchLink> [Blood Neoplasia] 2025 Nov 06; Vol. 3 (1), pp. 100181. <i>Date of Electronic Publication: </i>2025 Nov 06 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%2C+Inc%22">Elsevier, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9918841988906676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2950-3280 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2229503280%22">29503280 </searchLink><i>NLM ISO Abbreviation: </i>Blood Neoplasia <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41509995
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.bneo.2025.100181
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100181
    Titles:
      – TitleFull: Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Berdel AF
      – PersonEntity:
          Name:
            NameFull: Ronnacker J
      – PersonEntity:
          Name:
            NameFull: Wenge DV
      – PersonEntity:
          Name:
            NameFull: Kolloch LJ
      – PersonEntity:
          Name:
            NameFull: Berning P
      – PersonEntity:
          Name:
            NameFull: Angenendt L
      – PersonEntity:
          Name:
            NameFull: Brix TJ
      – PersonEntity:
          Name:
            NameFull: Westermann A
      – PersonEntity:
          Name:
            NameFull: Wethmar K
      – PersonEntity:
          Name:
            NameFull: Kessler T
      – PersonEntity:
          Name:
            NameFull: Kerkhoff A
      – PersonEntity:
          Name:
            NameFull: Mesters RM
      – PersonEntity:
          Name:
            NameFull: Reicherts C
      – PersonEntity:
          Name:
            NameFull: Mikesch JH
      – PersonEntity:
          Name:
            NameFull: Berdel WE
      – PersonEntity:
          Name:
            NameFull: Lenz G
      – PersonEntity:
          Name:
            NameFull: Schliemann C
      – PersonEntity:
          Name:
            NameFull: Stelljes M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 11
              Text: 2025 Nov 06
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2950-3280
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood neoplasia
              Type: main
ResultId 1